GLP1R and cancer: In essence, metformin, GLP-1 RAs, and SGLT2 inhibitors might be good candidates to fulfill these prerequisites and could be nearly as effective as bariatric (=metabolic) surgery in reducing cancer morbidity and mortality [37,38].